To Determine the Effects of Avosentan on Doubling of Serum Creatinine, End Stage Renal Disease and Death in Diabetic Nephropathy
NCT00120328
·
clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
2364
Enrollment
INDUSTRY
Sponsor class
Conditions
Diabetic Nephropathy
Interventions
DRUG:
SPP301
Sponsor
Speedel Pharma Ltd.